Reset filters

Search publications


Search by keyword
List by department / centre / faculty

No publications found.

 

Brain PET Imaging in Small Animals: Tracer Formulation, Data Acquisition, Image Reconstruction, and Data Analysis

Author(s): Bdair H; Kang MS; Ottoy J; Aliaga A; Kunach P; Singleton TA; Blinder S; Soucy JP; Leyton M; Rosa-Neto P; Kostikov A;

Positron emission tomography (PET) is a noninvasive functional imaging modality that involves in vivo detection of spatiotemporal changes in the binding of radioactive pharmaceuticals (a.k.a. PET tracers) to their target sites in different organs. The development of new PET tracers commonly invol ...

Article GUID: 38006502


Increased brain cholinergic innervation in isolated REM sleep behaviour disorder from prodromal multiple system atrophy

Author(s): Wickens RH; Postuma RB; de Villers-Sidani É; Pelletier A; Blinder S; Gagnon JF; Soucy JP; Montplaisir J; Bedard MA;

No abstract available

Article GUID: 37939636


Bayesian workflow for the investigation of hierarchical classification models from tau-PET and structural MRI data across the Alzheimer's disease spectrum

Author(s): Belasso CJ; Cai Z; Bezgin G; Pascoal T; Stevenson J; Rahmouni N; Tissot C; Lussier F; Rosa-Neto P; Soucy JP; Rivaz H; Benali H;

Background: Alzheimer's disease (AD) diagnosis in its early stages remains difficult with current diagnostic approaches. Though tau neurofibrillary tangles (NFTs) generally follow the stereotypical pattern described by the Braak staging scheme, the network degeneration hypothesis (NDH) has su ...

Article GUID: 37920382


Dosimetry of [18F]TRACK, the first PET tracer for imaging of TrkB/C receptors in humans

Author(s): Thiel A; Kostikov A; Ahn H; Daoud Y; Soucy JP; Blinder S; Jaworski C; Wängler C; Wängler B; Juengling F; Enger SA; Schirrmacher R;

Background: Reduced expression or impaired signalling of tropomyosin receptor kinases (Trk receptors) are found in a vast spectrum of CNS disorders. [18F]TRACK is the first PET radioligand for TrkB/C with proven in vivo brain penetration and on-target specific signal. Here we report dosimetry dat ...

Article GUID: 37870640


Lactate's behavioral switch in the brain: An in-silico model

Author(s): Soltanzadeh M; Blanchard S; Soucy JP; Benali H;

Emerging evidence emphasizes lactate's involvement in both physiological processes (energy metabolism, memory, etc.) and disease (traumatic brain injury, epilepsy, etc.). Furthermore, the usefulness of mathematical modeling in deciphering underlying dynamics of the brain to investigate lactate roles and mechanisms of action has been well established. ...

Article GUID: 37865309


A person with frontotemporal dementia shows increased metabolic rate across multiple brain regions after a series of tDCS sessions

Author(s): Roncero C; Nikelski J; Soucy JP; Lahiri D; Seixas-Lima B; Chertkow H;

No abstract available

Article GUID: 37182684


Primary and Secondary Progressive Aphasia in Posterior Cortical Atrophy

Author(s): Brodeur C; Belley É; Deschênes LM; Enriquez-Rosas A; Hubert M; Guimond A; Bilodeau J; Soucy JP; Macoir J;

Background: Posterior cortical atrophy (PCA) is a clinico-radiological syndrome characterized by a progressive decline in visuospatial/visuoperceptual processing. PCA is accompanied by the impairment of other cognitive functions, including language abilities. Methods: The present study focused o ...

Article GUID: 35629330


Radiosynthesis and In Vivo Evaluation of Four Positron Emission Tomography Tracer Candidates for Imaging of Melatonin Receptors

Author(s): Bdair H; Singleton TA; Ross K; Jolly D; Kang MS; Aliaga A; Tuznik M; Kaur T; Yous S; Soucy JP; Massarweh G; Scott PJH; Koeppe R; Spadoni G; Bedini A; Rudko DA; Gobbi G; Benkelfat C; Rosa-Neto P; Brooks AF; Kostikov A;

Melatonin is a neurohormone that modulates several physiological functions in mammals through the activation of melatonin receptor type 1 and 2 (MT1 and MT2). The melatonergic system is an emerging therapeutic target for new pharmacological interventions in the treatment of sleep and mood disorde ...

Article GUID: 35420022


Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [(18)F]-FEOBV

Author(s): Legault-Denis C; Aghourian M; Soucy JP; Rosa-Neto P; Dagher A; Aumont E; Wickens R; Bedard MA;

Background: Severe cholinergic degeneration is known to occur in Parkinson's disease (PD) and is thought to play a primary role in the cognitive decline associated with this disease. Although cholinergic losses occur in all patients with PD, cognitive performance remains normal for many of th ...

Article GUID: 34628195


CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment

Author(s): Brisson M; Brodeur C; Létourneau-Guillon L; Masellis M; Stoessl J; Tamm A; Zukotynski K; Ismail Z; Gauthier S; Rosa-Neto P; Soucy JP;

Since 1989, four Canadian Consensus Conferences on the Diagnosis and Treatment of Dementia (CCCDTDs) have provided evidence-based dementia diagnostic and treatment guidelines for Canadian clinicians and researchers. We present the results from the Neuroimaging and Fluid Biomarkers Group of the 5t ...

Article GUID: 33532543


Large-scale mGluR5 network abnormalities linked to epilepsy duration in focal cortical dysplasia.

Author(s): DuBois JM, Mathotaarachchi S, Rousset OG, Sziklas V, Sepulcre J, Guiot MC, Hall JA, Massarweh G, Soucy JP, Rosa-Neto P, Kobayashi E

To determine the extent of metabotropic glutamate receptor type 5 (mGluR5) network abnormalities associated with focal cortical dysplasia (FCD), we performed graph theoretical analysis of [11C]ABP688 PET binding potentials (BPND), which allows for quantification of mGluR5 availability. Undirected ...

Article GUID: 33401137


-   Page 1 / 3   >